Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk HCQ for COVID-19  Rodriguez et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Prospective study of 43 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.23) Rodriguez et al., Medicina Intensiva, Nov 2020 Favors HCQ Favors control

Severe infection due to the SARS-CoV-2 coronavirus: Experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic

Rodriguez et al., Medicina Intensiva, doi:10.1016/j.medine.2020.05.005
Nov 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Small prospective study of 43 hospitalized patients with 39 taking HCQ, showing unadjusted mortality relative risk RR 0.41, p=0.23.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 59.0% lower, RR 0.41, p = 0.23, treatment 8 of 39 (20.5%), control 2 of 4 (50.0%), NNT 3.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rodriguez et al., 9 Nov 2020, prospective, Spain, peer-reviewed, 13 authors, average treatment delay 8.0 days.
This PaperHCQAll
Severe infection due to the SARS-CoV-2 coronavirus: Experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic ଝ
A Rodríguez, G Moreno, J Gómez, R Carbonell, E Picó-Plana, C Benavent Bofill, R Sánchez Parrilla, S Trefler, E Esteve Pitarch, L Canadell, X Teixido, L Claverias, M Bodí
Objective: To describe the clinical and respiratory characteristics of a cohort of 43 patients with COVID-19 after an evolutive period of 28 days. Design: A prospective, single-center observational study was carried out. Setting: Intensive care. Patients: Patients admitted due to COVID-19 and respiratory failure. Interventions: None. Variables: Automatic recording was made of demographic variables, severity parameters, laboratory data, assisted ventilation (HFO: high-flow oxygen therapy and IMV: invasive mechanical ventilation), oxygenation (PaO2, PaO2/FiO2) and complications. The patients were divided into three groups: survivors (G1), deceased (G2) and patients remaining under admission (G3). The chi-squared test or Fisher exact test (categorical variables) was used, along with the Mann-Whitney U-test or Wilcoxon test for analyzing the differences between medians. Statistical significance was considered for p < 0.05.
Authorship Study conception and design: AR, MB, LC, GM, RC, and ST. Data acquisition and analysis: AR, MB, JG, GM, RC, EPP, ST, CBB, RSP, LC and XT. Data interpretation: AR, MB, LC, GM, RC, ESP, LC, ESP and EPP. Important intellectual contribution to the contents of the study: AR, MB, GM, RC, ESP, LC, and LC. Drafting of the manuscript: AR, MB, GM, and RC. Critical review of the contents of the article: JG, EPP, CBB, RSP, ST and XT. All the authors approved the final manuscript submitted for evaluation and possible publication. Conflicts of interest The authors declare that they have no conflicts of interest in relation to the present article. AR has received a research grant from Gilead Science for the study of nebulized antibiotics, and has received fees for teaching conferences from Biomerieux, Astellas, Pfizer, Thermo Fisher, MSD, Gilead, Shionogi and BRHAMS. There are no conflicts of interest in relation to the present study, however. The rest of the authors have no conflicts of interest. Appendix A. List of research members of the HJ23-COVID-19 Working Group Clinical laboratory Natalia Bastón-Paz, Carolina Sarvisé-Buil, Frederic Gómez-Bertomeu, Gemma Recio-Comi, Carla Martin-Grau, Silvia Montolio-Breva, Victoria Rivera-Moreno, Modest Sabaté-Piñol, Carmen Molina-Clavero, Nuria Serrat-Orús, Maria Teresa Sans-Mateu and Cristina Gutiérrez-Fornes. Epidemiology and prevention of nosocomial infections M. Montserrat Olona-Cabases. ICU Nursing Department Xavier Teixidó,..
Arentz, Yim, Klaff, Lokhandwala, Riedo et al., Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State, JAMA, doi:10.1001/jama.2020.6775
Barrasa, Rello, Tejada, Martín, Balziskueta et al., SARS-Cov-2 in Spanish Intensive Care: early experience with 15-day survival in Vitoria, Anaesth Crit Care Pain Med, doi:10.1016/j.accpm.2020.04.001
Bellomo, Ronco, Kellum, Mehta, Palevsky, the ADQI workgroup Acute renal failure ---definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Crit Care, doi:10.1186/cc2872
Díaz, Rodríguez, Martin-Loeches, Lorente, Mar Martín et al., Impact of obesity in patients infected with 2009 influenza A(H1N1), Chest
Ferrer, Pandemia por Covid-19: el mayor reto de la historia del intensivismo, Medicina Intensiva, doi:10.1016/j.medin.2020.04.002
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline Characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, JAMA, doi:10.1016/j.medin.2020.03.006
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Eng J Med, doi:10.1016/j.accpm.2020.04.001
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1001/jama.2020.5394
Kalil, Metersky, Klompas, Muscedere, Sweeney et al., Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis
Martin-Loeches, Schultz, Vincent, Alvarez-Lerma, Bos et al., Increased incidence of co-infection in critically ill patients with influenza, Intensive Care Med
Moreno, Rodríguez, Reyes, Gomez, Sole-Violan et al., Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study, Intensive Care Med, doi:10.1186/cc2872
Ranieri, Rubenfeld, Thompson, Ferguson, Acute respiratory distress syndrome: the Berlin Definition. ARDS Definition Task Force, JAMA
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area, JAMA, doi:10.1001/jama.2020.6775
Rubio, Cabre, Saralegui-Reta, Martin, Zapata, Recomendaciones éticas para la toma de decisiones difíciles en las unidades de cuidados intensivos ante la situación excepcional de crisis por la pandemia por COVID-19: revisión rápida y consenso de expertos, Med Intensiva, doi:10.1016/j.medin.2020.04.006
Sedes, Sanz, Saera, Rodríguez-Rey, Ortega et al., Plan de contingencia para los servicios de medicina intensiva frente a lapandemia COVID-19, Medicina Intensiva, doi:10.1016/j.medin.2020.04.002
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1016/S2213-2600(20)30079-5
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1056/NEJMoa2002032
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop